5 August 2014

Minerva IPO and Acquisition



Minerva Neurosciences Inc. completed its initial public offering of nearly 5.5 million shares, which began trading on 1 July 2014 on the NASDAQ Global Market under the ticker symbol «NERV». Prior to the IPO, Minerva acquired all shares in Mind-NRG S.A., a Swiss pre-clinical stage pharmaceutical company.

Walder Wyss AG has acted as Swiss legal advisor to Minerva. The team was led by Urs P. Gnos (Partner, Corporate/M&A) and included Markus Vischer (Partner, Corporate/M&A), Hubertus Hillerström (Managing Associate, Banking Finance), Fabienne Claudon (Associate, Corporate/M&A), Samuel Lieberherr (Associate, Corporate/M&A), Janine Corti (Associate, Tax) and Manuel B. Mühlestein (Trainee, Corporate/M&A).

News

News

5 August 2014

Minerva IPO and Acquisition

Minerva Neurosciences Inc. completed its initial public offering of nearly 5.5 million shares, which began trading on 1 July 2014 on the NASDAQ Global Market under the ticker symbol «NERV». Prior to the IPO, Minerva acquired all shares in Mind-NRG S.A., a Swiss pre-clinical stage pharmaceutical company.

Walder Wyss AG has acted as Swiss legal advisor to Minerva. The team was led by Urs P. Gnos (Partner, Corporate/M&A) and included Markus Vischer (Partner, Corporate/M&A), Hubertus Hillerström (Managing Associate, Banking Finance), Fabienne Claudon (Associate, Corporate/M&A), Samuel Lieberherr (Associate, Corporate/M&A), Janine Corti (Associate, Tax) and Manuel B. Mühlestein (Trainee, Corporate/M&A).